These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26391871)

  • 41. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
    Hong C; Lee H; Oh M; Kang CY; Hong S; Park SH
    J Immunol; 2006 Nov; 177(10):6747-57. PubMed ID: 17082588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining DNA Vaccine and AIDA-1 in Attenuated
    Mei Y; Zhao L; Liu Y; Gong H; Song Y; Lei L; Zhu Y; Jin Z; Ma S; Hu B; Sun Q; Liu H
    Cancer Immunol Res; 2017 Jun; 5(6):503-514. PubMed ID: 28468915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
    J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
    Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
    Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
    Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
    J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
    Ryan CM; Schell TD
    J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.
    Lambert LA; Gibson GR; Maloney M; Durell B; Noelle RJ; Barth RJ
    Cancer Res; 2001 Jan; 61(2):641-6. PubMed ID: 11212262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
    Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.
    Chen Q; Jackson H; Shackleton M; Parente P; Hopkins W; Sturrock S; MacGregor D; Maraskovsky E; Tai TY; Dimopoulos N; Masterman KA; Luke T; Davis ID; Chen W; Cebon J
    Cancer Immun; 2005 Mar; 5():5. PubMed ID: 15755075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of specific immune responses by polycation-based vaccines.
    Lührs P; Schmidt W; Kutil R; Buschle M; Wagner SN; Stingl G; Schneeberger A
    J Immunol; 2002 Nov; 169(9):5217-26. PubMed ID: 12391240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer.
    Kono M; Wakisaka R; Komatsuda H; Hayashi R; Kumai T; Yamaki H; Sato R; Nagato T; Ohkuri T; Kosaka A; Ohara K; Kishibe K; Kobayashi H; Hayashi T; Takahara M
    Head Neck; 2024 Aug; 46(8):2056-2067. PubMed ID: 38390628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
    Chakrabarti L; Morgan C; Sandler AD
    PLoS One; 2015; 10(6):e0129237. PubMed ID: 26079374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.